About Panavance Therapeutics
We are focused on giving every patient the best possible chance to live a healthy and cancer-free life. Our clinical-stage drug GP-2250 is bringing new hope to the fight against cancer through truly novel science.
Who We Are
Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the outcomes and quality of life for cancer patients. Panavance, a US Delaware company, is located in Berwyn, PA. It was founded in 2021 and is a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie.
Panavance’s lead program, misetionamide (also known as GP-2250), is a tumor cell selective and broadly active small molecule with a unique dual mechanism of action of selectively disrupting the energy metabolism of cancer cells leading to cancer cell death as well as impacting nuclear factor-κB (“NFκB”) which effects cancer cells’ ability for protein synthesis and DNA transcription thereby restricting cancer cell growth and proliferation.
The Company is advancing towards the initiation of two registration directed clinical studies expected to start in 2024: a Phase 2/3 study of GP-2250 for the treatment of ovarian cancer and a pivotal Phase 3 clinical trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients, a population for which there are no FDA approved agents. GP-2250’s unique mechanism of action and extensive preclinical data supports broad oncology utility with the potential to be effective in additional indications, including melanoma, squamous cell, breast and colorectal cancers.
Why We Exist
We get up every morning with a clear focus on making a significant improvement in clinical outcomes and the lives of cancer patients everywhere. Like the mechanism of GP-2250, our mission is to disrupt cancer’s energy.
What We Deliver
Our clinical stage asset, GP-2250, has the potential to make a meaningful impact across diverse oncological disease states and therapeutic applications by targeting the primary source of cancer cell energy production with its unique and patent-pending mechanism of action.
What’s In A Name?
Why We’re Panavance.
Pan-disease
We believe that our highly tumor cell selective asset may offer a broad benefit across and beyond cancers and in combination with existing treatments.
Pan-therapeutic
GP-2250 has broad therapeutic potential across stages of disease including neoadjuvant, adjuvant and advanced/metastatic disease.
Pan-avance
We are focused on advancing the effectiveness of cancer treatments and quality of life for patients everywhere.
Leadership
Meet the Panavance leadership team.
We are led by a highly capable and passionate team that wholeheartedly shares our mission.
Science
Discover our novel mechanism of action.
Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.